StockNews.com initiated coverage on shares of Evoke Pharma (NASDAQ:EVOK – Get Rating) in a research note issued to investors on Monday. The firm set a “sell” rating on the specialty pharmaceutical company’s stock.
Evoke Pharma Stock Performance
Shares of EVOK stock opened at $1.94 on Monday. The company has a current ratio of 7.08, a quick ratio of 6.91 and a debt-to-equity ratio of 1.22. The business’s fifty day simple moving average is $2.58 and its 200-day simple moving average is $2.50. Evoke Pharma has a 12-month low of $1.37 and a 12-month high of $16.80. The company has a market cap of $6.48 million, a PE ratio of -0.72 and a beta of 0.37.
Evoke Pharma (NASDAQ:EVOK – Get Rating) last released its earnings results on Tuesday, March 21st. The specialty pharmaceutical company reported ($0.53) earnings per share (EPS) for the quarter. The firm had revenue of $0.80 million during the quarter. Evoke Pharma had a negative net margin of 327.91% and a negative return on equity of 175.51%.
About Evoke Pharma
Evoke Pharma, Inc is a pharmaceutical company, which engages in the development of drugs for the treatment of gastrointestinal disorders and diseases. It also develops Gimoti, with promotility and anti-emetic effects, for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women with diabetes mellitus.
Further Reading
- Get a free copy of the StockNews.com research report on Evoke Pharma (EVOK)
- MarketBeat Week in Review – 4/17 – 4/21
- 2 Industrial Strength Dividend Stocks Melting Up
- Proctor & Gamble Is Going To Set A New High
- AutoNation’s Plans are Keeping Analysts Around
- Netflix Increases Buybacks: Can It Complete A Reversal In 2023?
Receive News & Ratings for Evoke Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evoke Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
